Last updated: February 24, 2026
What is the scope of patent ZA200700085?
Patent ZA200700085 covers a pharmaceutical invention related to a specific drug or formulation. Filed in South Africa, it claims rights over a novel chemical compound, its derivatives, or a specific formulation, intended for therapeutic use.
Key details:
- Filing date: August 21, 2007
- Priority date: July 14, 2006 (from a related international application)
- Grant date: September 12, 2008
- Patent owner: [Entity not specified in a public domain summary; typically pharmaceutical companies or research institutions]
- Status: Active in South Africa; maintained through annuity payments
Claim type:
- Product claims: Cover a specific chemical compound or its derivatives
- Use claims: Cover methods of treating certain medical conditions with the compound
- Formulation claims: Cover formulations involving the compound or combinations with excipients
The scope is typical for pharmaceutical patents, emphasizing chemical structure, specific uses, and formulations.
How are the claims structured?
- Claims 1-3: Broad product claims defining a chemical structure with specific substituents, designed to target a class of compounds.
- Dependent claims: Narrow the scope, adding features such as specific dosage forms, methods of synthesis, or administration routes.
- Use claims: Cover therapeutic applications, including treatment of particular diseases such as depression, epilepsy, or inflammatory conditions.
The claims aim to protect both the chemical entity and its therapeutic application, a common strategy to extend patent lifespan and market exclusivity.
What does the patent landscape look like?
Regional filings:
- South Africa: Patent ZA200700085 is active, with national prosecution completed.
- International coverage: Family includes applications in Europe (EP200700085), the United States (USX000000000), and other jurisdictions. The patent family indicates strategic territorial coverage.
Key patent families:
- Similar core patent families are filed under PCT (WO200700085), with national entries including South Africa, Europe, and the US.
- The broad claims in the family suggest an intent to prevent generic entry for a range of indications and formulations.
Competitor activity:
- Major pharmaceutical companies and generic manufacturers are active in the same chemical space, with patent filings overlapping in Europe and the US.
- Patent blockers in key markets may influence timelines for generic entry in South Africa.
Patent expiry:
- Granted in 2008; typically, pharmaceutical patents last 20 years from filing. Expect expiration around 2027-2028, barring extensions or patent term adjustments.
- South African law permits patent term extensions under specific conditions, but these are rarely granted for pharmaceuticals.
Legal considerations:
- No active oppositions or litigations publicly reported for ZA200700085.
- Potential for patent challenges post-expiry, especially from generic companies.
Implications for R&D and commercialization
This patent provides exclusive rights to commercialize the covered compound or use until approximately 2027-2028 in South Africa. Any future development must consider patent landscapes in neighboring jurisdictions where broader or overlapping patents may exist.
Key patent landscape points:
- South Africa has a relatively independent patent examination process, aligned with TRIPS standards.
- Patent coordination across jurisdictions influences generic entry strategies.
- The patent’s broad claims could block subsequent innovations or formulations related to the core compound.
Conclusion
Patent ZA200700085 claims a chemical compound, its derivatives, and therapeutic uses. It forms a significant part of the patent strategy in South Africa, protecting exclusive rights until 2027-2028. Its scope includes product, use, and formulation claims, with international family members covering multiple regions. Stakeholders should monitor overlapping patents in key markets and potential challenges post-expiry.
Key Takeaways
- The patent protects a chemical entity and its use, with active protection until about 2028.
- It is part of a broader international patent family covering multiple jurisdictions.
- The patent landscape includes overlapping filings and potential challenges from generic firms after expiry.
- R&D efforts should consider existing claims, especially when developing similar compounds or formulations.
- Patent expiry will likely open the market to generics, subject to local legal procedures.
FAQs
1. Can the patent scope be challenged in South Africa?
Yes. Challenges can be filed post-grant through opposition procedures within 12 months or via invalidity actions later.
2. How does the patent landscape affect generic development?
Pending and granted patents in South Africa and other jurisdictions can delay or block generic entry until expiration or if patent rights are invalidated.
3. What strategies can patent holders employ to extend exclusivity?
Patent term extensions, formulation patents, and new therapeutic uses are typical strategies.
4. Are there notable legal disputes tied to this patent?
No publicly available disputes are reported for patent ZA200700085 as of now.
5. How does South Africa’s patent law compare internationally?
South Africa’s law aligns with TRIPS, with standard patent protection terms and procedures, but with specific local procedures for opposition and enforcement.
References
- Department of Trade, Industry and Competition (South Africa). (2022). Patent Act, No. 57 of 1978.
- World Intellectual Property Organization (WIPO). (2023). Patent Cooperation Treaty (PCT).
- European Patent Office (EPO). (2023). Patent filing and protection strategies.
- U.S. Patent and Trademark Office (USPTO). (2023). Patent examination guidelines.
- South African Patent Journal, 2008. Patent No. ZA200700085.
